deferoxamine has been researched along with Varices in 1 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the degree of depigmentation with the use of deferoxamine mesylate (DM) in patients with postsclerotherapy hyperpigmentation treated with polydocanol (POL) for telangiectasias and reticular veins (0." | 7.71 | Cutaneous hyperpigmentation following venous sclerotherapy treated with deferoxamine mesylate. ( Dilley, RB; Henriquez, JA; Lopez, L, 2001) |
| "To evaluate the degree of depigmentation with the use of deferoxamine mesylate (DM) in patients with postsclerotherapy hyperpigmentation treated with polydocanol (POL) for telangiectasias and reticular veins (0." | 3.71 | Cutaneous hyperpigmentation following venous sclerotherapy treated with deferoxamine mesylate. ( Dilley, RB; Henriquez, JA; Lopez, L, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lopez, L | 1 |
| Dilley, RB | 1 |
| Henriquez, JA | 1 |
1 other study available for deferoxamine and Varices
| Article | Year |
|---|---|
Cutaneous hyperpigmentation following venous sclerotherapy treated with deferoxamine mesylate.
Topics: Adult; Deferoxamine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hyperpigmentat | 2001 |